Emergent BioSolutions | EBS - Ebitda


Emergent BioSolutions reported $-113.5M in EBITDA for its fiscal quarter ending in March of 2023.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 100.31M 21.24M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Myriad Genetics USD 14.3M 4M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Pacira USD 38.71M 10.65M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Xoma USD 2.52M 7.98M Jun/2024